Home / Europe / Netherlands / Life Sciences & Healthcare

Life Sciences & Healthcare

Law Firm in the Netherlands specialised in Life Sciences & Healthcare

Our dedicated Life Sciences & Healthcare team specialises in advising clients in the pharmaceutical, medical devices, cosmetics, novel food and agriculture industry. ​

We have extensive experience in serving our clients, who represent 80% of the leading industry players. Because many of us have in-house experience, we understand your unique challenges and needs and have the ability to provide you with hands-on commercial advice.​

Our team operates across all relevant legal disciplines involved in supporting this sector. This includes industry specific regulatory and compliance work, intellectual property matters and competition law advice. We also advise on commercial, data privacy, employment, real estate and corporate matters. Our expertise allows us to meet both local and international business needs of our clients.

"Good and timely follow up, very collaborative and good overall communication."

The Legal 500 EMEA, 2024

"CMS’ team offer a deep understanding of the legal specificities of the medical devices industry."

The Legal 500 EMEA, 2024

"Knowledgeable about our market environment, very pragmatic and able to translate legal means to business outcomes, easy to work with."

The Legal 500 EMEA, 2024

"Our contacts at CMS NL differ from many other lawyers in that they deliver practically usable results. They point out potential risks, but at the same time commit to an outcome and don’t leave us guessing. After the consultation, we are definitely smarter and know our options."

The Legal 500 EMEA, 2024

"CMS is able to effectively structure and handle complex legal matters."

Chambers Europe, 2024

"CMS is able to effectively structure and handle complex legal matters."

Chambers Europe, 2024

Their litigation abilities are excellent, with in-firm expertise available on related legal topics.

The Legal500 EMEA, 2022

Clients particularly value the team's commercial awareness, praising their "good insights into what is going on in the pharmaceutical market in the Netherlands."

Chambers Europe, 2022

The team is recommended for its "specific knowledge regarding tenders and projects in the field of medical appliances."

Chambers Europe 2021

The firm has "an excellent knowledge of pharmaceutical regulations and a practical mindset."

Chambers Europe 2021

‘Speedy responses and practical advice in pharma and corporate law matters.’

The Legal 500 EMEA, 2020

"really brilliant" , "broad network" and that the firm "co-ordinates things well".

Chambers Europe-wide, 2020

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

Choose an area

E-Health
With technology and digital innovation at the forefront of many advancements in the life sciences industry and healthcare delivery, companies are cons
Medical Devices and Diagnostics
Medical devices and diagnostics are quickly evolving, integrating innovative tech solutions that use and generate increasing amounts of data. They hav
Novel Food (incl. Cannabis/CBD)
An ever increasing awareness of climate change and the need to modify our behaviour to address it, is leading to a huge demand for more sustainable &n
microscope with bottles of chemicals in forefront
Pharmaceuticals
In the last decade, it has become increasingly complex and costly to obtain marketing authorisation. On top of this,  market access has become &n
Subscribe to Life Sciences & Healthcare topics
Stay up-to-date with our client services.
03/01/2024
CMS Life Sciences & Healthcare Global Brochure
With big deals fuelling record levels of M&A activity, a steady stream of innovative and disruptive technologies, new and increasingly complex regulatory challenges and a thriving start-up community...

Feed

19/07/2024
A healthy balance between novelty and sufficiency for a claimed therapeutic...
The question of novelty and sufficiency of second medical use claims in light of clinical trial prior art has been addressed by the EPO Boards of Appeal on a number of occasions. In recent decision T...
11/07/2024
Cannabis law and legislation in the Netherlands
Medical use The Dutch Opium Act distinguishes drugs with a low risk of harm (‘soft drugs’) from drugs with a high risk of harm (‘hard drugs’). Cannabis is listed under the soft drugs category...
26/06/2024
Updated CMS Expert Guide to Cannabis law and legislation
CMS Expert Guide on cannabis law and legislation gives stakeholders detailed and updated information on the latest developments in cannabis regulation in key markets.  The Guide now covers 33 jurisdictions...
21/06/2024
CMS Advises Syncona on Series B Financing Roud in respect of iOnctura B.V.
CMS has advised Syncona on leading a EUR 80m Series B Financing Round in respect of iOnctura B.V. Syncona is a leading healthcare company listed on the London Stock Exchange, focused on founding, building...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...
21/05/2024
Consultation of the European Commission on Vifor's commitments concerning...
In response to the Preliminary Assessment stating the potential abuse of its dominant position, Vifor proposed several commitments to rectify the potential competition law infringement. The European Commission...
16/05/2024
A broader interpretation of "substance or composition" - good news for...
A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The back­ground:Art­icle 53(c)...
08/05/2024
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicines  The Medicines Act is the primary law on advertising of medicines. In addition, the Dutch Civil Code...
11/04/2024
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...
25/03/2024
Patentability of inventions relating to diagnostic methods at the EPO
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...